Medicare Enrolled
Dr. Amber Sobuto, D.O.
Student in an Organized Health Care Education/Training Program · Wynnewood, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sobuto from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sobuto?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sobuto
Dr. Amber Sobuto is a student in an organized health care education/training program specialist in Wynnewood, PA, with 13 years of NPI registration. Based on federal Medicare data, Dr. Sobuto performed 71,790 Medicare services across 3,983 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sobuto received a total of $3,908 from 42 pharmaceutical and/or device companies across 163 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in student in an organized health care education/training program. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sobuto is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years in practice
▲ Top 0% volume in PA
$3,908 industry payments
Medicare Practice Summary
Medicare Utilization ↗71,790
Medicare services
Top 0% in PA for student in an organized health care education/training program
3,983
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~5,522 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
17,850 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 13,600 | $43 | $86 |
| Denosumab injection (Prolia/Xgeva) | 7,260 | $18 | $30 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
5,680 | $6 | $27 |
| Paclitaxel chemotherapy injection | 5,292 | $0 | $15 |
| Iron infusion (Monoferric) | 4,400 | $16 | $40 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
3,120 | $6 | $20 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,548 | $0 | $10 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,556 | $8 | $30 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
1,442 | $10 | $35 |
| Injection, granisetron hydrochloride, 100 mcg | 1,140 | $0 | $208 |
| Injection, fulvestrant, 25 mg | 780 | $8 | $180 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
586 | $93 | $140 |
| Anti-nausea injection (Aloxi/palonosetron) | 490 | $1 | $60 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
457 | $96 | $250 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
456 | $76 | $500 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
449 | $13 | $40 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
440 | $132 | $190 |
| Iron level test | 434 | $6 | $25 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
434 | $9 | $35 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
357 | $22 | $100 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
324 | $10 | $40 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
305 | $61 | $105 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
281 | $2 | $215 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
215 | $12 | $50 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
122 | $21 | $85 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
117 | $4 | $20 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
117 | $6 | $15 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
115 | $6 | $20 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
111 | $48 | $110 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
106 | $7 | $400 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
105 | $53 | $100 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
100 | $1 | $5 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
95 | $47 | $150 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
88 | $25 | $80 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 75 | $20 | $75 |
| New patient office visit, complex (60-74 min) | 68 | $151 | $295 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
66 | $1 | $10 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
57 | $1 | $9 |
| Vitamin B-12 level test A blood test that measures the amount of vitamin B-12 in your body. |
54 | $15 | $75 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
50 | $120 | $239 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
50 | $1 | $10 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 46 | $333 | $1,500 |
| CA 19-9 tumor antigen test A blood test that measures the level of CA 19-9, a substance that can be found in the blood of some people with cancer. This quantitative analysis detects and measures the specific tumor antigen. |
38 | $20 | $75 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
38 | $17 | $55 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
37 | $16 | $40 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
35 | $2 | $14 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
34 | $40 | $150 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
33 | $7 | $17 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
32 | $19 | $47 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
32 | $14 | $40 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
27 | $9 | $50 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
23 | $26 | $100 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
23 | $133 | $248 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
32.5% high complexity
58.5% medium
9.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,908
Total received (2018-2024)
Avg $651/year across 6 years
Top 9% in PA for student in an organized health care education/training program
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
42
Companies
163
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,575 (91.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$333 (8.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$646
2023
$420
2022
$328
2020
$114
2019
$1,000
2018
$1,401
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Boehringer Ingelheim Pharmaceuticals, Inc.
$122
SOBI, INC
$100
ABBVIE INC.
$59
AstraZeneca Pharmaceuticals LP
$50
PFIZER INC.
$43
BeiGene USA, Inc.
$29
Bayer Healthcare Pharmaceuticals Inc.
$27
Janssen Biotech, Inc.
$27
Gilead Sciences, Inc.
$23
TerSera Therapeutics LLC
$23
GlaxoSmithKline, LLC.
$23
Eisai Inc.
$22
Amgen Inc.
$19
Rigel Pharmaceuticals, Inc.
$16
Daiichi Sankyo Inc.
$16
Genentech USA, Inc.
$16
Astellas Pharma US Inc
$15
Novartis Pharmaceuticals Corporation
$15
Top 3 companies account for 43.6% of 2024 payments
All-time payments by company (2018-2024) ›
Celgene Corporation
$566
E.R. Squibb & Sons, L.L.C.
$322
Genentech USA, Inc.
$277
AstraZeneca Pharmaceuticals LP
$274
PFIZER INC.
$264
Boehringer Ingelheim Pharmaceuticals, Inc.
$247
Incyte Corporation
$240
JAZZ PHARMACEUTICALS INC.
$150
Lilly USA, LLC
$147
Novartis Pharmaceuticals Corporation
$141
Seagen Inc.
$137
Janssen Biotech, Inc.
$104
Amgen Inc.
$103
SOBI, INC
$100
TESARO, Inc.
$85
Seattle Genetics, Inc.
$85
ABBVIE INC.
$59
Karyopharm Therapeutics Inc.
$49
GlaxoSmithKline, LLC.
$42
Merck Sharp & Dohme Corporation
$39
Gilead Sciences, Inc.
$36
Takeda Pharmaceuticals U.S.A., Inc.
$36
Foundation Medicine, Inc.
$34
BeiGene USA, Inc.
$29
Bayer Healthcare Pharmaceuticals Inc.
$27
Alexion Pharmaceuticals, Inc.
$25
GENZYME CORPORATION
$24
TerSera Therapeutics LLC
$23
Sobi, Inc
$22
Eisai Inc.
$22
Bayer HealthCare Pharmaceuticals Inc.
$22
Kite Pharma, Inc.
$18
TAIHO ONCOLOGY, INC.
$18
Merck Sharp & Dohme LLC
$18
Regeneron Healthcare Solutions, Inc.
$17
Rigel Pharmaceuticals, Inc.
$16
Daiichi Sankyo Inc.
$16
Astellas Pharma US Inc
$15
Puma Biotechnology, Inc.
$15
AMAG Pharmaceuticals, Inc.
$15
AbbVie, Inc.
$14
Taiho Oncology, Inc.
$14
Top 3 companies account for 29.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · Abraxane · Alecensa · Avastin · BAVENCIO · BOSULIF · BRUKINSA · Blincyto · CALQUENCE · CHANTIX · CYRAMZA · DARZALEX · DOPTELET · ELIQUIS · ENHERTU · EPKINLY · ERLEADA · Enhertu · Erleada · FERAHEME · FOUNDATIONONE · FRUZAQLA · IBRANCE · IMFINZI · INLYTA · Itovebi · JAKAFI · KEYTRUDA · KISQALI · LIBTAYO · LONSURF · LYNPARZA · Lenvima · Lonsurf · MONJUVI · NINLARO · Neulasta · Nubeqa · OFEV · OJJAARA · OPDIVO · PLUVICTO · PROMACTA · Perjeta · Pomalyst · REBLOZYL · Revlimid · Rezlidhia · SARCLISA · SPRYCEL · SUTENT · TAGRISSO · TASIGNA · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · Venclexta · Vitrakvi · XALKORI · XPOVIO · Xtandi · Yescarta · ZEJULA · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (92%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 9% for student in an organized health care education/training program in PA.
Geographic Context
Student in an organized health care education/training programs within 10 mi
7,705
Per 100K population
894.7
County median income
$111,521
Nearest hospital
MAIN LINE HOSPITAL LANKENAU
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sobuto is a mixed practice specialist, with above-average Medicare volume (top 0% in PA), with low-engagement industry engagement in the top 9% of PA peers.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sobuto experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Sobuto performed 17,850 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sobuto receive payments from pharmaceutical companies?
Yes. Dr. Sobuto received a total of $3,908 from 42 companies across 163 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sobuto's costs compare to other student in an organized health care education/training programs in Wynnewood?
Dr. Sobuto's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sobuto) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Student In An Organized Health Care Education/training Programs in Wynnewood
Browse student in an organized health care education/training programs in Wynnewood ranked by procedure volume and transparency data.
Highest volume
Top Student In An Organized Health Care Education/training Programs in PA
Student in an organized health care education/training programs ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Student In An Organized Health Care Education/training Programs in PA
Which PA student in an organized health care education/training programs receive the most from drug and device companies.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology